A 45-year-old man with type 1 diabetes presents with malaise, nausea, and abdominal discomfort shortly after initiating a new antidiabetic drug. Laboratory evaluation reveals blood glucose of 300 mg/dL, serum bicarbonate of 16 mEq/L, an elevated anion gap of 18, and ketones detected in the urine. Which of the following medications is most likely responsible for this presentation?
সমাধান
সঠিক উত্তর: Option A
This 45-year-old man with type 1 diabetes presents with symptoms of malaise, nausea, and abdominal discomfort soon after starting a new antidiabetic medication. His laboratory results show:
- Blood glucose: 300 mg/dL (hyperglycemia)
- Serum bicarbonate: 16 mEq/L (low, indicating metabolic acidosis)
- Elevated anion gap: 18 (reflecting an anion gap metabolic acidosis)
- Ketones in urine: confirming ketosis
These findings are characteristic of diabetic ketoacidosis (DKA).
Among the listed medications, empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, a class of drugs that increase renal glucose excretion and are commonly used in type 2 diabetes.
However, in susceptible patients, especially those with type 1 diabetes or insulin deficiency, SGLT2 inhibitors have been associated with euglycemic diabetic ketoacidosis or typical DKA due to:
- Depletion of glucose leading to lower insulin doses
- Increased glucagon levels
- Enhanced lipolysis and ketogenesis
Even though blood glucose may not be profoundly elevated, patients develop ketosis and metabolic acidosis, as seen in this case.
Why Other Options Are Less Likely:
- Metformin: Associated primarily with lactic acidosis, not ketoacidosis. This patient’s presentation and ketones in urine argue against lactic acidosis.
- Pioglitazone: A thiazolidinedione; it improves insulin sensitivity but is not linked to ketoacidosis.
- Glipizide: A sulfonylurea that stimulates insulin secretion; unlikely to cause ketoacidosis, and instead tends to increase insulin levels, preventing ketosis.
Key Points:
- Empagliflozin (SGLT2 inhibitors) can cause ketoacidosis, even with near-normal glucose levels.
- Monitor patients for signs of DKA, especially those with type 1 diabetes starting SGLT2 inhibitors.
- Presence of anion gap metabolic acidosis with ketosis shortly after starting an SGLT2 inhibitor should raise suspicion for drug-induced ketoacidosis.
- Blood glucose: 300 mg/dL (hyperglycemia)
- Serum bicarbonate: 16 mEq/L (low, indicating metabolic acidosis)
- Elevated anion gap: 18 (reflecting an anion gap metabolic acidosis)
- Ketones in urine: confirming ketosis
These findings are characteristic of diabetic ketoacidosis (DKA).
Among the listed medications, empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, a class of drugs that increase renal glucose excretion and are commonly used in type 2 diabetes.
However, in susceptible patients, especially those with type 1 diabetes or insulin deficiency, SGLT2 inhibitors have been associated with euglycemic diabetic ketoacidosis or typical DKA due to:
- Depletion of glucose leading to lower insulin doses
- Increased glucagon levels
- Enhanced lipolysis and ketogenesis
Even though blood glucose may not be profoundly elevated, patients develop ketosis and metabolic acidosis, as seen in this case.
Why Other Options Are Less Likely:
- Metformin: Associated primarily with lactic acidosis, not ketoacidosis. This patient’s presentation and ketones in urine argue against lactic acidosis.
- Pioglitazone: A thiazolidinedione; it improves insulin sensitivity but is not linked to ketoacidosis.
- Glipizide: A sulfonylurea that stimulates insulin secretion; unlikely to cause ketoacidosis, and instead tends to increase insulin levels, preventing ketosis.
Key Points:
- Empagliflozin (SGLT2 inhibitors) can cause ketoacidosis, even with near-normal glucose levels.
- Monitor patients for signs of DKA, especially those with type 1 diabetes starting SGLT2 inhibitors.
- Presence of anion gap metabolic acidosis with ketosis shortly after starting an SGLT2 inhibitor should raise suspicion for drug-induced ketoacidosis.